The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mo ...

The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...

Ricercatori anglo-americani hanno scoperto la struttura molecolare dei filamenti della proteina Tau che partecipa al processo neurodegenerativo della malattia di Alzheimer. La scoperta apre ...

Doctors also typically recommend that patients with both obesity and sleep apnea lose weight to ease their symptoms — and the substance in Zepbound, a compound called tirzepatide, is extremely ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...

The letter went to Xcel Peptides, SwissChems, Summit Research and Prime Peptides, four online companies it said were selling unapproved GLP-1 drugs, including semaglutide and tirzepatide.

Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or ...